




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 491/048, 491/08, 495/04, 495/08, A61K 31/42 // (C07D 491/048, 307:00, 209:00) (C07D 491/08, 307:00, 209:00) (C07D 495/04, 333:00, 209:00) (C07D 495/08, 333:00, 209:00)		A1	(11) International Publication Number: WO 96/15130
			(43) International Publication Date: 23 May 1996 (23.05.96)
(21) International Application Number: PCT/US95/12751			
(22) International Filing Date: 31 October 1995 (31.10.95)			
(30) Priority Data: 08/339,979 15 November 1994 (15.11.94) US			
(60) Parent Application or Grant			
(63) Related by Continuation US 08/339,979 (CIP) Filed on 15 November 1994 (15.11.94)			
(71) Applicant (for all designated States except US): THE UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BARBACHYN, Michael, R. [US/US]; 1216 Miles Avenue, Kalamazoo, MI 49001 (US). THOMAS, Richard, C. [US/US]; 2166 Wild Cherry Lane, Kalamazoo, MI 49009 (US). CLEEK, Gary, J. [US/US]; Apartment 1623, 308 West Candlewyck, Kalamazoo, MI 49001 (US).			

(54) Title: BICYCLIC OXAZINE AND THIAZINE OXAZOLIDINONE ANTIBACTERIALS

(57) Abstract

Phenylloxazolidinone compounds of formula (I) or a pharmaceutically acceptable salt thereof characterized by a bicyclic thiazine or oxazine substituent. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as *Bacteroides* spp. and *Clostridia* spp. species, and acid-fast organisms such as *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium* spp.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

BICYCLIC OXAZINE AND THIAZINE OXAZOLIDINONE ANTIBACTERIALS

Background of the Invention

5 The subject invention discloses new and useful phenoxyoxazolidinone compounds characterized by having either a bicyclic thiazine or oxazine substituent. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic
10 organisms such as *Bacteroides spp.* and *Clostridia spp.* species, and acid-fast organisms such as *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium spp.*

Information Disclosure

15 The present compounds are related by their phenoxyoxazolidinone ring structure to those disclosed in the publications below except that the subject compounds have either a bicyclic thiazine or oxazine phenyl substituent. The instant compounds have useful antibacterial activity.

20 PCT/US94/08904 application discloses oxazolidinone antibacterial compounds having either a morpholine or thiomorpholine substituent.
PCT/US93/03570 application discloses oxazolidinones containing a substituted diazine moiety and their uses as antimicrobials.

PCT/US92/08267 application discloses substituted aryl and heteroaryl-phenyl-oxazolidinones useful as antibacterial agents.

25 PCT/US89/03548 application discloses 5'indolinyl-5β-amidomethoxyoxazolidinones, 3-(fused-ring substituted)phenyl-5β-amidomethoxyoxazolidinones, and 3-(nitrogen substituted)phenyl-5β-amidomethoxyoxazolidinones which are useful as antibacterial agents.

30 Other references disclosing various oxazolidinones include US Patent 4,801,600, 4,921,869, Gregory W. A., et al., *J. Med. Chem.*, 32, 1673-81 (1989); Gregory W. A., et al., *J. Med. Chem.*, 33, 2569-78 (1990); Wang C., et al., *Tetrahedron*, 45, 1323-26 (1989); and Brittelli, et al., *J. Med. Chem.*, 35, 1156 (1992).

35 European Patent Publication 352,781 discloses phenyl and pyridyl substituted phenyl oxazolidinones.

European Patent Publication 316,594 discloses 3-substituted styryl oxazolidinones.

European Patent Publication 312,000 discloses phenylmethyl and


pyridinylmethyl substituted phenyl oxazolidinones.

Summary of the Invention

In one aspect the subject invention is a compound of structural Formula I:

5

10



15


Formula I

20

More preferred compounds, a subset of those described by structural Formula I, are represented by structural Formula II:

25

30



Formula II

35

5 or pharmaceutically acceptable salts thereof wherein:

X is (a) O,
(b) S,
(c) SO,
(d) SO₂;

10 R¹ is independently H, F, Cl or OMe;

R² is (a) hydrogen,
(b) C₁-C₈ alkyl optionally substituted with one or more of the following:
F, Cl, hydroxy, C₁-C₈ alkoxy, C₁-C₈ acyloxy,
(c) C₃-C₆ cycloalkyl,
15 (d) amino,
(e) C₁-C₈ alkylamino,
(f) C₁-C₈ dialkylamino,
(g) C₁-C₈ alkoxy;

a is 0 to 3;

20 b is 0 to 2;

c is 0 to 2 (provided b and c cannot both be 0);

d is 0 to 2; and

e is 0 to 2 (provided d and e cannot both be 0).

25 In another aspect, the subject invention is directed toward a method for treating microbial infections in humans or other warm-blooded animals by administering to a patient in need thereof an effective amount of a compound of Formula I or II as described above. The compound can be administered in a pharmaceutical composition either orally, parenterally or topically. Preferably the 30 compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day, more preferably, from about 3.0 to about 50 mg/kg of body weight/day.

Detailed Description of the Invention

35 The present invention discloses novel substituted bicyclic oxazinyl- or thiazinylphenyloxazolidinones of structural Formula I and II as described above.

The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, particularly aerobic gram-positive bacteria, including multiply-resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast bacteria such as

5 as *Mycobacterium tuberculosis* and other mycobacterial species.

"Alkyl" means carbon atom chains having the designated number of carbon atoms which can be either straight chained or branched.

10 "Alkoxy" means the designated number of carbon atoms attached to an oxygen forming such groups as methoxy (-OCH₃), ethyloxy, butyloxy, etc. and isomeric forms thereof.

"Acyloxy" means the designated number of carbon atoms to form an organic acid where the OH group has been deleted, such as acetyl, CH₃ CO-; benzoyl, C₆H₅CO-.

15 "Cycloalkyl" means the designated number of carbon atoms forming cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. and isomeric forms thereof.

"Amino" means an NH₂, "alkylamino" is where one of the hydrogen positions is replaced by an alkyl and "dialkylamino" is where both hydrogens are replaced by an alkyl group.

20 "Pharmaceutically acceptable salts" are acid addition salts which can be prepared by any of the art recognized means. Typical, acid addition salts include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, malate, succinate, tartrate, cyclohexanesulfamates, methanesulfonates, ethanesulfonates, benzenesulfonates, toluenesulfonates, fumarates and other pharmaceutically acceptable counter ions for amines.

25 Preferably X is S.

The R¹ substituents are preferably both fluorine and, more preferably, fluorine and hydrogen.

30 The R² substituent is preferably hydrogen, methyl, dichloromethyl, hydroxymethyl or methoxy. More preferably R² is hydrogen, methoxy or methyl. It is most preferred that R² is methyl.

The preferred absolute configuration at C-5 of the oxazolidinone ring of compounds claimed in this invention is as represented in the structures of Formula I and II. This absolute configuration is called (S) under the Cahn-Ingold-Prelog nomenclature system. It is this (S)-enantiomer which is pharmacologically active.

35 The racemic mixture is useful in the same way and for the same purpose as the pure (S)-enantiomer; the difference is that twice as much racemic material must be

used to produce the same antibacterial effect. It will be apparent to one skilled in the art that when an additional chiral center(s) is present in the bicyclic oxazine or thiazine fragment of compounds of structural Formula I and II, then diastereomers are possible. These diastereomers, in racemic and enantiomerically enriched forms, 5 are also within the scope of the compounds of Formula I and II of the invention.

Preferred compounds of Formula I are

(S)-N-[[3-[3-fluoro-4-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Example 1);
(S)-N-[[3-[3-fluoro-4-[(1*S*,4*S*)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Example 2);
(S)-N-[[3-[3-fluoro-4-[(1*S*,4*S*)-2-thia-2,2-dioxo-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Example 3);
(S)-N-[[3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-*c*]pyrrol-5(3*H*)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Example 4)
15 (S)-N-[[3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-*c*]pyrrol-5(3*H*)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, S-oxide (Example 5)
(S)-N-[[3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-*c*]pyrrol-5(3*H*)-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, S,S-dioxide (Example 6)
20 cis-(S)-N-[[3-[3-fluoro-4-[3-oxa-7azabicyclo[3.3.0]octane-7-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Exmaple 7)
(S)-N-[[3-[3-fluoro-4-[(1*R*,4*R*)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(S)-N-[[3-[3-fluoro-4-(2-thia-6-azabicyclo[3.2.0]heptan-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
25 (S)-N-[[3-[3-fluoro-4-(3-thia-6-azabicyclo[3.2.0]heptan-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(S)-N-[[3-[3-fluoro-4-(3-thia-7-azabicyclo[3.3.1]nonan-7-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
30 (S)-N-[[3-[3-fluoro-4-(3-thia-9-azabicyclo[3.3.1]nonan-9-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(S)-N-[[3-[3-fluoro-4-(2-thia-6-azabicyclo[3.2.1]octan-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
35 (S)-N-[[3-[3-fluoro-4-(2-thia-6-azabicyclo[3.3.1]nonan-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(S)-N-[[3-[3-fluoro-4-(7-thia-3-azabicyclo[4.2.1]nonan-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(9-thia-3-azabicyclo[3.3.1]nonan-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(3-oxa-6-azabicyclo[3.2.0]heptan-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

5 (S)-N-[[3-[3-fluoro-4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(3-oxa-7-azabicyclo[3.3.1]nonan-7-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(3-oxa-9-azabicyclo[3.3.1]nonan-9-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

10 (S)-N-[[3-[3-fluoro-4-(9-oxa-3-azabicyclo[3.3.1]nonan-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

15 (S)-N-[[3-[3-fluoro-4-(2-oxa-6-azabicyclo[3.2.1]octan-6-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(3-oxa-7-azabicyclo[4.2.0]octan-7-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

20 (S)-N-[[3-[3-fluoro-4-(6-oxa-2-azabicyclo[3.2.1]octan-2-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

(S)-N-[[3-[3-fluoro-4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; and

25 (S)-N-[[3-[3-fluoro-4-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

The most preferred compound is (S)-N-[[3-[3-fluoro-4-[(1*S*,4*S*)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Example 2).

30 (S)-N-[[3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-*c*]pyrrol-5(3*H*)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Example 4)

(S)-N-[[3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-*c*]pyrrol-5(3*H*)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, S,S-dioxide (Example 6)

35 The pharmaceutical compositions of this invention may be prepared by combining the compounds of Formula I or II of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically

acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, 5 suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this 10 invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate 15 amounts of the active component, that is, the compound of Formula I according to this invention.

The quantity of active component, that is the compound of Formula I or II according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, 20 the potency of the particular compound, the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.

In therapeutic use for treating, or combatting, bacterial infections in warm-blooded animals, the compounds or pharmaceutical compositions thereof will be 25 administered orally and/or parenterally at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about 0.1 to about 100, more preferably about 3.0 to about 50 mg/kg of body 30 weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the 35 optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also

be divided into multiple doses for administration, e.g., two to four times per day.

The compounds of Formula I or II according to this invention are administered parenterally, i.e., by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for 5 parenteral administration will generally contain a pharmaceutically acceptable amount of the compound according to Formula I or II as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3-7. Suitable buffering agents 10 include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents. The compound according to Formula I generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml of solution. 15 The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage.

The preferred method of preparation of oxazolidinones of Formula I and II in enantiomerically pure form is depicted in Charts I-IV..

As shown in Chart I, bicyclic oxazines and thiazines (commercially available 20 or known in the literature), such as (1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptane (X = O) and (1*S*,4*S*)-2-thia-5-azabicyclo[2.2.1]heptane (X = S) of structure 1, are reacted with a functionalized nitrobenzene 2 (Y = halogen or trifluoromethanesulfonate) in the presence of a suitable base such as *N,N*-diisopropylethylamine and in a suitable solvent such as acetonitrile, tetrahydrofuran (THF) or ethyl acetate at ambient to 25 reflux temperature to provide the adducts 3. When X = O, the nitro group of 3 is then reduced by catalytic hydrogenation in the presence of a suitable catalyst such as 10% palladium on carbon or W-2 Raney nickel, and in a suitable solvent such as ethyl acetate, tetrahydrofuran, aqueous tetrahydrofuran, methanol and mixtures thereof, to furnish the anilines 4. In the case where X = S, the nitro group of 3 can 30 be reduced by the action of sodium hydrosulfite in aqueous tetrahydrofuran at ambient temperature to 55 °C to give the anilines 4. Alternatively, reduction of the nitro group of 3 (X = S) can be accomplished by catalytic hydrogenation in the presence of a suitable catalyst, such as platinum on sulfide carbon or W-2 Raney nickel, and in an appropriate solvent system, for example aqueous tetrahydrofuran. 35 The latter conditions are especially useful in that the reaction mixture is simply filtered through Celite® or the like to remove the catalyst and the filtrate containing

the aniline 4 is directly used in the next step. To this end, the anilines 4 are converted to their benzyl ($R^3 = CH_2Ph$) or methyl ($R^3 = CH_3$) carbamate derivatives 5, employing standard Schotten-Baumann conditions or other variations known to one skilled in the art. The urethanes 5 are then deprotonated with a suitable base 5 such as *n*-butyllithium, lithium diisopropylamide, or lithium bis(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran or *N,N*-dimethylformamide and at a suitable temperature such as -78 to -60°C to give a lithiated intermediate which is then treated with commercially available (-)-(R)-glycidyl butyrate. Warming to ambient temperature then directly affords the 5-(hydroxymethyl)oxazolidinones 6 in 10 enantiomerically enriched form. Compound 6 is then converted to the corresponding mesylate 7 ($R^4 =$ methanesulfonyl) or aryl sulfonate 7 ($R^4 =$ ArSO₂, for example *p*-toluenesulfonyl) by the action of, for example, methanesulfonyl chloride/pyridine or methanesulfonyl chloride/triethylamine/dichloromethane or *p*-toluenesulfonyl chloride/pyridine.

15 As illustrated in Chart II, the resultant sulfonate derivative 7 is then reacted with an azide source such as sodium or potassium azide in an aprotic solvent such as *N,N*-dimethylformamide (DMF) or 1-methyl-2-pyrrolidinone, optionally in the presence of a catalyst such as 18-crown-6, at a temperature of 50-90 °C to afford the azide 8. The azide is then reduced by hydrogenation with palladium on carbon or a 20 platinum catalyst in an appropriate solvent such as ethyl acetate or methanol to give the corresponding amine 9. Alternatively, and preferably in the case where X = S, the azide can be reduced by treatment with a trivalent phosphorus compound such as triphenylphosphine in a suitable solvent such as tetrahydrofuran followed by the addition of water. Alternatively, the mesylate or aryl sulfonate group of 25 compounds 7 can be displaced with potassium phthalimide in acetonitrile at reflux temperature to give the intermediate phthalimide 10. The phthalimide 10 is then deprotected by treatment with aqueous methyl amine in refluxing ethanol to afford the amine 9. In yet another alternative, the mesylate 7 is reacted with ammonium hydroxide in hot isopropanol or isopropanol/tetrahydrofuran, preferably in a sealed 30 reaction vessel, to directly give the amine 9. The amine 9 is then acylated by reactions known to those skilled in the art to give oxazolidinones of structure 11. For example, the amine can be reacted with an acid chloride or anhydride in a basic solvent such as pyridine at a temperature ranging from -30 to 30 °C to provide the 35 acylated compound 11 ($R^2 =$ optionally substituted alkyl). It will be apparent to one skilled in the art that other acyl groups within the scope of this invention can be

readily appended to the amine **9** by standard acylation techniques, for example those highlighted in March, J. "Advanced Organic Chemistry", 4th ed.; John Wiley & Sons: New York, 1992; pp 417-425, to give additional examples of **11**. The compounds of structure **11** represent examples of bicyclic oxazine- and thiazine-substituted 5 oxazolidinone antibacterial agents of Formula II, which are the subject of this invention.

As shown in Chart III, the oxazolidinones **11**, themselves examples of antibacterial agents of Formula II, can be further elaborated to additional compounds of Formula II. Specifically, **11** (X = S) can be oxidized to the 10 corresponding sulfoxide(s) **12** (X = SO) with sodium metaperiodate in a mixture of water and methanol. It will be apparent to one skilled in the art that both *endo*- and *exo*- sulfoxides are possible, and both isomeric forms, as well as mixtures thereof, are within the scope of this invention. In addition, compounds **11** or **12** can be oxidized to the corresponding sulfones **13** (X = SO₂) by treatment with 4- 15 methylmorpholine *N*-oxide and catalytic osmium tetroxide in aqueous acetone. It will be apparent to those skilled in the art that alternative conditions for oxidizing **11** (X = S) to **12** or **13** are known, for example those highlighted in March, J. "Advanced Organic Chemistry", 4th ed.; John Wiley & Sons: New York, 1992; pp 1201-1202.

20 As shown in Chart IV synthesis of compounds which incorporate a thienopyrrolidine begins with reduction of the diester **14** to the diol **15** using lithium aluminum hydride as the reducing agent. Compound **15** is then converted to the bis-mesylate **16** by reaction with methanesulfonyl chloride and a trialkylamine base. Cyclization of **16** to the thienopyrrolidine **17** is carried out by reaction with sodium 25 sulfide, and compound **17** is debenzylated to the thienopyrrole **18** by reaction with hydrogen in the presence of a suitable catalyst such as palladium on carbon. The compound of example 4 is then prepared from **18** by following the procedures outlined in Charts I and II (but substituting **18** for **1**). The compounds of Examples 5 and 6 are prepared by oxidation of the compound of Example 4, using the same 30 procedures as shown in Chart III.

Antimicrobial activity was tested *in vivo* using a Murine Assay procedure. Groups of female mice were injected intraperitoneally with bacteria which were thawed just prior to use and suspended in brain heart infusion with 4% Brewer's yeast UC9213 (*Staphylococcus aureus*) or brain heart infusion (*Streptococcus species*). 35 Antibiotic treatment at six dose levels per drug was administered on hour and five

hours after infection by either oral or subcutaneous routes. Survival was observed daily for six days. ED₅₀ values based on mortality ratios were calculated using probit analysis. The subject compounds were compared against a well-known antimicrobial (Vancomycin) as a control. The data is shown in Table 1.

5

Table 1
In Vivo Activity Against *S. aureus* UC®9213

10	Example No.	ED ₅₀ (mg/kg)	
		Example, PO	Vancomycin, SC
	1	7.7	11.2
	2	4.2	4.0
	4	4.3	-
	5	10.0	-
15	6	3.5	-

It will be apparent to those skilled in the art that the described synthetic procedures are merely representative in nature and that the use of alternative bicyclic oxazines and thiazines known in the patent and open literature allows for 20 the preparation of additional examples of structural Formula I.

EXAMPLE 1: (S)-N-[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]acetamide

Step 1: 4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoronitrobenzene

A mixture of commercially available (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane 5 hydrochloride (0.200 g, 1.47 mmol), dipotassium hydrogen phosphate (1.030 g, 5.90 mmol) and 3,4-difluoronitrobenzene (0.195 mL, 1.77 mmol) in dimethyl sulfoxide (6 mL) was stirred at ambient temperature under a N₂ atmosphere. TLC analysis (5% MeOH/CHCl₃) after 3 h revealed the starting nitrobenzene was consumed. The 10 reaction mixture was diluted with H₂O and (60 mL) and extracted with CHCl₃. The combined organic extracts were washed with H₂O and brine, dried over Na₂SO₄, 15 filtered and concentrated under reduced pressure to a yellow solid. Chromatography over silica gel (60 g), eluting with a gradient of 0-2% MeOH/CHCl₃, afforded, after concentration of appropriate fractions, 0.314 g (90%) of the title compound as a yellow solid with mp 106.5-108 °C and MS(EI) 238 (M⁺).

15

Step 2: N-(carbobenzyloxy)-4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoroaniline

A solution of 4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoronitrobenzene (0.160 g, 0.672 mmol) in 3:1 THF/H₂O (4 mL) was treated with 20 acetic acid (0.115 mL) and then 10% palladium/carbon (0.020 g) under a N₂ stream. The atmosphere was replaced with H₂ (balloon) by repeated evacuation and filling and the mixture stirred at ambient temperature. After 2 h, TLC analysis (6% CH₃CN/CHCl₃) revealed the reduction to be complete. The reaction mixture was 25 filtered through Celite® and the filtrate immediately placed under an atmosphere of N₂ and treated with K₂CO₃ (0.464 g, 3.36 mmol) followed by benzyl chloroformate (0.117 mL, 0.864 mmol). TLC analysis (6% CH₃CN/CHCl₃) after 0.5 h revealed the reaction to be complete. The reaction mixture was concentrated under reduced 30 pressure and chromatographed over silica gel (20 g), eluting with a gradient of 1-5% CH₃CN/CHCl₃. Concentration of appropriate fractions afforded 0.226 g (98 %) of the title compound as a white solid with mp 120-121 °C and MS(EI) 342 (M⁺).

Step 3: (R)-[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]methanol

A solution of N-(carbobenzyloxy)-4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoroaniline (0.169 g, 0.494 mmol) in dry THF (2 mL) was cooled to -78 °C 35 under a N₂ atmosphere and then treated with *n*-butyllithium (0.312 mL of a 1.6 M

solution in hexane, 0.499 mmol). After stirring 10 min at -78 °C, the reaction mixture was treated with (*R*)-glycidyl butyrate (0.070 mL, 0.499 mmol). When the addition was completed, the cooling bath was removed and the mixture allowed to stir at ambient temperature overnight, during which time an off-white precipitate 5 appeared. TLC analysis (5% MeOH/CHCl₃) revealed the reaction to be complete. The reaction mixture was treated with ca. 5 drops of saturated aqueous NH₄Cl, which made the reaction mixture a homogeneous solution. The reaction mixture was concentrated under reduced pressure to an off-white solid. Chromatography 10 over silica gel, eluting with a gradient of 1-5% MeOH/CHCl₃, afforded, after concentration of appropriate fractions, 0.116 g (84%) of the title compound as a white solid with mp 138-140 °C and MS(EI) 308 (M⁺). In addition, 0.018 g (10%) of a second component, identified as the butyrate ester of the title compound by ¹H NMR analysis, was obtained as an amber oil.

15 Step 4: (R)-[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethylmethanesulfonate

A solution of (*R*)-[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methanol (0.765 g, 2.48 mmol) in dry CH₂Cl₂ (30 mL) was cooled to 0 °C under a N₂ atmosphere and treated with Et₃N (0.518 mL, 20 3.73 mmol) followed by methanesulfonyl chloride (0.202 mL, 2.61 mmol). TLC analysis (5% MeOH/CHCl₃) after 0.5 h revealed the reaction to be complete. The reaction mixture was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo* to give 0.992 g (ca. 100%) of the title compound as a tan solid. An analytical sample was prepared by recrystallization from 5% CH₂Cl₂/i-PrOH. 25 This sample had mp 124.5-126 °C and MS(EI) 386 (M⁺).

Step 5: (R)-[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethylazide

A solution of (*R*)-[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methylmethanesulfonate (0.869 g, 2.25 mmol) in dry DMF (10 mL) was treated with solid NaN₃ (0.732 g, 11.3 mmol) at ambient 30 temperature under N₂. The mixture was then heated to 65 °C and reaction progress monitored by TLC. After 7.5 h at this temperature, TLC analysis (5% MeOH/CHCl₃) revealed the reaction to complete. The reaction mixture was diluted 35 with EtOAc (100 mL), washed with H₂O (3 x 15 mL) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 0.692 g (92%) of the title

compound as a tan solid. An analytical sample was prepared by recrystallization from 1:1 EtOAc/hexane as an off-white solid with mp 101-102.5 °C and MS(EI) 333 (M⁺).

5 Step 6: (S)-N-[[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

A solution of (R)-[[3-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]azide (0.652 g, 1.96 mmol) in MeOH (20 mL) and CH₂Cl₂ (10 mL) was treated with 10% palladium/carbon (0.095 g) under a 10 N₂ stream. The atmosphere was then replaced with H₂ (balloon) by repeated evacuation and filling and the mixture stirred at ambient temperature under H₂. After 3 h, TLC analysis (5% MeOH/CHCl₃) revealed the reduction to be complete. The reaction mixture was filtered through Celite® and the filtrate concentrated under reduced pressure. The crude 5-(aminomethyl)oxazolidinone was dissolved in 15 CH₂Cl₂ (20 mL) and treated with pyridine (0.190 mL, 2.35 mmol) and then acetic anhydride (0.222 mL, 2.35 mmol). After 0.5 h, TLC analysis (5% MeOH/CHCl₃) indicated the acetylation to be complete. The reaction mixture was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo* to give an off-white solid. Chromatography over silica gel (70 g), eluting with a gradient of 1-3% 20 MeOH/CHCl₃, afforded, after concentration of appropriate fractions, 0.517 g (76%) of the title oxazolidinone antibacterial agent as a white solid with mp 60-65 °C and MS(EI) 349 (M⁺).

EXAMPLE 2: (S)-N-[[3-[3-fluoro-4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

Step 1: 4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoronitrobenzene

A mixture of commercially available (1S,4S)-2-thia-5-azabicyclo[2.2.1]heptane (0.500 g, 3.30 mmol), diisopropylethylamine (1.434 mL, 8.24 mmol) and 3,4-30 difluoronitrobenzene (0.437 mL, 3.96 mmol) in dry acetonitrile (15 mL) was heated to reflux temperature under a N₂ atmosphere for 1 h and then cooled to ambient temperature overnight. The reaction mixture was concentrated under reduced pressure to give a yellow syrup. Chromatography over silica gel (50 g), eluting with chloroform, afforded, after concentration of appropriate fractions, 0.700 g (84%) of 35 the title compound as a yellow solid with mp 97-98 °C and MS(EI) 254 (M⁺).

Step 2: N-(carbobenzyloxy)-4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoroaniline

A solution of 4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoronitrobenzene (1.64 g, 6.46 mmol) in 20% H₂O/THF (50 mL) was treated with 5 platinum on sulfide carbon (0.200 g) under a N₂ stream. The atmosphere was replaced with H₂ (balloon) by repeated evacuation and filling. After 12 h TLC analysis revealed a significant amount of starting material still remained. The reaction mixture was transferred to a Parr apparatus and shaken under 45 psi H₂. 10 TLC analysis after 2 h indicated some starting material still remained. The reaction mixture was filtered through Celite® and the filtrate, containing a mixture of the desired aniline intermediate and starting nitrobenzene derivative, was cooled to 0 °C and treated with NaHCO₃ (2.170 g, 25.8 mmol) and benzyl chloroformate (1.02 mL, 7.10 mmol). After 0.5 h the reaction mixture was concentrated under reduced pressure to a yellow/green syrup. This material was dissolved in CHCl₃, washed 15 with H₂O and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. Filtration through a plug of silica gel, eluting with 20-30% EtOAc/hexane, afforded, after concentration of appropriate fractions, a mixture of starting nitrobenzene derivative and the title compound. This material taken-up in 20% H₂O/THF (50 mL) and treated with W-2 Raney nickel (ca. 0.400 g). The reaction mixture was 20 shaken on a Parr apparatus under 45 psi H₂. After 3 h the reaction mixture was filtered through Celite® and the filtrate cooled to 0 °C and treated with NaHCO₃ (2.00 g, 23.8 mmol) followed by benzyl chloroformate (0.600 mL, 4.19 mmol). After 0.5 h the reaction mixture was concentrated under reduced pressure and the residue 25 chromatographed over silica gel (125 g), eluting with 10-20% EtOAc/hexane, to afford, after concentration of appropriate fractions, 2.20 g (95%) of the title compound as a yellow solid mp 91-93 °C and MS(EI) 358 (M⁺).

Step 3: (R)-[3-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethanol

30 A solution of N-(carbobenzyloxy)-4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluoroaniline (0.359 g, 1.00 mmol) in dry THF (4 mL) under N₂ was cooled to -78 °C and then treated with *n*-butyllithium (0.633 mL of a 1.6 M solution in hexane, 1.01 mmol). The reaction mixture was stirred at -78 °C for 15 min and then treated with (R)-glycidyl butyrate (0.151 mL, 1.00 mmol). When the addition was complete, 35 the cooling bath was removed and the reaction mixture allowed to warm to ambient temperature overnight. TLC analysis (5% MeOH/CHCl₃) indicated the reaction was

complete but a small amount of the butyrate ester of the title compound was present. The addition of 5 drops of a 25 wt.% solution of NaOMe/MeOH, followed by stirring for 20 min at room temperature, was effective in converting this intermediate to the title compound. The reaction mixture was treated with

5 saturated aqueous NH₄Cl (10 drops) and then concentrated under reduced pressure to an oil. This material was dissolved in CH₂Cl₂ and washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo* to give a crude product. Chromatography over silica gel (50 g), eluting with 1-3% MeOH/CHCl₃, afforded, after concentration of appropriate fractions, 0.132 g (41%) of the title compound as

10 an oil. Trituration with EtOAc afforded a precipitate, which was isolated and dried *in vacuo* to give an off-white solid with mp 156-157 °C and MS(EI) 324 (M⁺).

Step 4: (R)-[3-[4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methylmethanesulfonate

15 A solution of (R)-[3-[4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methanol (1.68 g, 5.19 mmol) in dry CH₂Cl₂ (100 mL) under N₂ was cooled to 0 °C and treated with Et₃N (0.793 mL, 5.70 mmol) followed by methanesulfonyl chloride (0.442 mL, 5.70 mmol). After 0.5 h at this temperature, the reaction appeared to be complete by TLC analysis (5% MeOH/CHCl₃). The mixture was washed with H₂O, saturated aqueous NaHCO₃ and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo* to give 1.65 g (79%) of the title compound as a white solid with mp 139-142 °C and MS(EI) 402 (M⁺).

25 Step 5: (S)-N-[3-[3-fluoro-4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methylacetamide

A mixture of (R)-[3-[4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methylmethanesulfonate (1.56 g, 3.88 mmol), 1:1 THF/*i*-PrOH (4 mL) and 30% NH₄OH (4 mL) was heated to 95 °C in a sealed tube for 14 h and then cooled to ambient temperature. TLC analysis (5% MeOH/CHCl₃) revealed the reaction to be complete. The mixture was diluted with CH₂Cl₂ (75 mL), washed with saturated aqueous NaHCO₃ (15 mL) and brine (15 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a syrup. The crude 5-(aminomethyl)oxazolidinone intermediate was dissolved in CH₂Cl₂ (75 mL) and treated with pyridine (0.345 mL, 4.27 mmol) and acetic anhydride (0.403 mL, 4.27 mmol) at ambient temperature. After 1 h, TLC analysis (5% MeOH/CHCl₃)

indicated the acetylation to be complete. The reaction mixture was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to an amber solid. Chromatography over silica gel (125 g), eluting with 1-3% MeOH/CHCl₃, afforded, after concentration of appropriate fractions, 1.23 g (87%) of the title oxazolidinone antibacterial agent as a solid with mp 90-95 °C and MS(EI) 365 (M⁺).

EXAMPLE 3: (S)-N-[[3-[3-fluoro-4-[(1S,4S)-2-thia-2,2-dioxo-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methylacetamide

10 A solution of (S)-N-[[3-[3-fluoro-4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methylacetamide (0.300 g, 0.82 mmol) in 25% H₂O/acetone (16 mL) was treated at ambient temperature with 4-methylmorpholine-N-oxide (0.288 g, 2.47 mmol) followed by osmium tetroxide (0.102 mL of a 2.5 wt.% solution in *tert*-butanol, 0.008 mmol). After 18 h, TLC analysis (10% MeOH/CHCl₃) revealed the oxidation was complete. The reaction mixture was treated with saturated aqueous NaHSO₃ and then extracted with CHCl₃. The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was chromatographed over silica gel (10 g), eluting with 1-3% MeOH/CHCl₃, to afford, after concentration of appropriate fractions, 0.321 g (98%) of the title oxazolidinone antibacterial agent as a white solid with mp 95-105 °C.

EXAMPLE 4: (S)-N-[[3-[3-fluoro-4-(tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methylacetamide

25 Step 1: cis-1-(Phenylmethyl)-3,4-pyrrolidinedimethanol
(*cis*)-1-(Phenylmethyl)-3,4-pyrrolidinedicarboxylic acid, dimethyl ester was prepared according to the procedure of Y. Terao, et al (*Chem. Pharm. Bull.*, 1985, 33, 2762-66). To a stirred solution of this diester (12.14 g, 43.8 mmol) in dry THF (175 mL) under N₂ cooled to 0 °C was added dropwise a solution of lithium aluminum hydride (1M in THF, 87 mL, 87 mmol) over 15 min. The reaction mixture was stirred at 0 °C for 1 h, then at RT for 18 h. The reaction mixture was cooled to 0 °C and quenched with successive addition of H₂O (3.2 mL), 5 N NaOH (3.2 mL) and H₂O (11.7 mL). The reaction mixture became very thick and stirring was difficult. The reaction mixture was diluted with ether (500 mL) and filtered through a small pad of celite. The filter cake was washed with ether (250 mL). The filtrate was washed

with H_2O (1 x 300 mL) and the organics were dried (MgSO_4), filtered and concentrated to afford 9.3 g (41.8 mmol, 96%) of the desired diol and a thick yellow oil. Used without further purification. HRMS (FAB) calcd for $\text{C}_{13}\text{H}_{19}\text{NO}_2\text{H}$ 222.1494, found 222.1490.

5

Step 2: *cis*-1-(Phenylmethyl)-3,4-di(methylsulfonyloxy)methylpyrrolidine

To a stirred solution of *cis*-1-(phenylmethyl)-3,4-pyrrolidinedimethanol (9.2 g, 41.6 mmol) in CH_2Cl_2 (240 mL) cooled to 0 °C was added triethylamine (29 mL, 208.1 mmol) followed by methanesulfonyl chloride (8.1 mL, 104.0 mmol). The reaction mixture was stirred at 0 °C for 15 min, then at RT for 1.5 h. The reaction mixture was poured into H_2O (240 mL) and the phases were separated. The aqueous phase was extracted with CH_2Cl_2 (1 x 100 mL). The combined organics were dried (MgSO_4), filtered and concentrated. The residue was purified by flash chromatography using ethyl acetate as the eluent to afford 14.2 g (37.5 mmol, 90%) of the desired bis-mesylate as a thick yellow oil. HRMS (EI) calcd for $\text{C}_{15}\text{H}_{23}\text{NO}_6\text{S}_2$ 377.0967, found 377.0958.

Step 3: Hexahydro-5-(phenylmethyl)-1*H*-thieno[3,4-c]pyrrole

To a stirred solution of *cis*-1-(phenylmethyl)-3,4-di(methylsulfonyloxy)methylpyrrolidine (9.2 g, mmol), in dry DMSO (48 mL) was added anhydrous sodium sulfide (5.7 g, 73.3 mmol). The dark reaction mixture was heated at 120 °C for 18 h. The cooled reaction mixture was poured into ice H_2O (150 mL). The resulting mixture was extracted with ether (3 x 200mL). The combined organics were dried (MgSO_4), filtered and concentrated. The resulting residue was purified by flash chromatography using ethyl acetate as the eluent to afford 4.2 g (19.1 mmol, 78%) of the desired product as a thick yellow oil. HRMS (EI) calcd for $\text{C}_{13}\text{H}_{17}\text{NS}$ 219.1082, found 219.1080. Anal. Calcd for $\text{C}_{13}\text{H}_{17}\text{NS}$: C, 71.19; H, 7.81; N, 6.39. Found: C, 70.82; H, 7.83; N, 6.35.

30 Step 4:

Hexahydro-1*H*-thieno[3,4-c]pyrrole, hydrochloride

To a stirred solution of hexahydro-5-(phenylmethyl)-1*H*-thieno[3,4-c]pyrrole (1.2 g, 5.3 mmol) in CH_2Cl_2 (21 mL) cooled to 0 °C was added dropwise *via* syringe 1-chloroethylchloroformate (1.15 mL, 10.7 mmol). The reaction mixture was stirred at 0 °C for 20 min, then at RT for 90 min. The reaction mixture was concentrated. The resulting residue was purified by flash chromatography using 25 % ethyl acetate in hexane as the eluent to afford 611.3 mg (2.6 mmol, 49%) of 1-

chloroethylcarbamate. The column was then washed with 20% methanolic ammonia in CHCl_3 to afford 160.5 mg (1.24 mmol, 23 %) of desired amine as the free base. The 1-chloroethylcarbamate (611.3 mg, 2.6 mmol) was dissolved in methanol (15 mL) and heated at reflux for 90 min. The cooled reaction mixture was concentrated to afford 408.0 mg (2.5 mmol, 47%) of the desired amine as the HCl salt (based on chlorocarbamate). mp 149-151 °C; HRMS (EI) calcd for $\text{C}_6\text{H}_{11}\text{NS}$ 129.0612, found 129.0614. Anal. Calcd for $\text{C}_6\text{H}_{12}\text{ClNS}$: C, 43.50; H, 7.30; N, 8.45; Cl: 21.39; S: 19.35. Found: C, 43.39; H, 7.23; N, 8.24; Cl: 21.08; S: 19.12.

10 Step 5: 5-(2-Fluoro-4-nitrophenyl)-hexahydro-1*H*-thieno[3,4-c]pyrrole
To a stirred suspension of hexahydro-5-1*H*-thieno[3,4-c]pyrrole, hydrochloride (147.3 mg, 0.89 mmol) in acetonitrile (5 mL) was added 3,4-fluoronitrobenzene (0.11 mL, 0.98 mmol) followed by diisopropylethyl amine (0.36 mL, 2.05 mmol). The homogeneous reaction mixture was heated at reflux for 18 h. The cooled reaction mixture was concentrated. The resulting residue was diluted with EtOAc (50 mL) and washed with saturated aqueous NH_4Cl (1 x 25 mL). The aqueous layer was extracted with EtOAc (1 x 30 mL). Combined organics were washed with saturated NaHCO_3 (1 x 40 mL), brine (1 x 40 mL), dried (MgSO_4), filtered and concentrated. The residue was purified by flash chromatography using 20 % EtOAc in hexane as the eluent to afford 202.5 mg (0.75 mmol, 89%) of the desired nitro compound as a bright yellow solid. mp 107-109 °C; Anal. calcd for $\text{C}_{12}\text{H}_{13}\text{FN}_2\text{O}_2\text{S}$: C, 53.72; H, 4.88; N, 10.44; S: 11.95. Found: C, 53.38; H, 5.03; N, 10.34; S: 11.89.

Step 6: 3-[3-Fluoro-4-(tetrahydro-1*H*-thieno[3,4-c]pyrrol-5(3*H*)-yl)phenylcarbamic acid, phenylmethylester
To a stirred suspension of 5-(2-fluoro-4-nitrophenyl)-hexahydro-1*H*-thieno[3,4-c]pyrrole (1.44 g, 5.4 mmol) in ethanol (70 mL) was added 2 M aqueous CuSO_4 (2.9 mL). This mixture was cooled to 0 °C and sodium borohydride (1.10 g, 26.8 mmol) was added portionwise. (Caution: Very exothermic!) The dark reaction mixture was then heated at reflux for 2 h. The cooled reaction mixture was partitioned between EtOAc and H_2O . The phases were separated. The aqueous phase was extracted with EtOAc (3 x 100 mL). The combined organics were dried (MgSO_4), filtered and concentrated. The resulting dark residue was dissolved in acetone/ H_2O (2:1, 60 mL). This stirred solution was cooled to 0 °C and solid NaHCO_3 (1.35 g, 16.1 mmol) was added followed by benzylchloroformate (1.9 mL, 13.4 mmol). The reaction mixture was stirred at 0 °C for 15 min, then at RT for 2 h. The reaction

mixture was quenched by careful addition of 10 % aqueous NaHSO_4 (30 mL). The reaction mixture was poured into EtOAc (250 mL) and the phases were separated. The aqueous layer was extracted with EtOAc (1 x 100 mL). The combined organic layers were dried (MgSO_4), filtered and concentrated. The residue was purified by 5 flash chromatography using 20% EtOAc in hexane to afford 1.6 g (4.3 mmol, 81 %) of the desired carbamate: mp 101-102 °C; Anal. Calcd for $\text{C}_{20}\text{H}_{21}\text{FN}_2\text{O}_2\text{S}$: C, 64.50; H, 5.68; N, 7.52; S: 8.61. Found: C, 64.33; H, 5.56; N, 7.53; S: 8.61.

Step 7: (5R)-3-[3-Fluoro-4-(tetrahydro-1*H*-thieno[3,4-c]pyrrol-5(3*H*)-yl)phenyl]-5-(hydroxymethyl)-2-oxazolidinone

To stirred solution of 3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-c]pyrrol-5(3*H*)-yl)phenylcarbamic acid, phenylmethyl ester (1.36 g, 3.6 mmol) dry THF (14 mL) under N_2 cooled to -78 °C was added n-butyllithium (1.6 M in hexane, 2.4 mL, 3.8 mmol). The reaction mixture was stirred at -78 °C for 35 min and then *R*-(*-*)-15 glycidylbutyrate (0.54 mL, 3.8 mmol) was added. The reaction mixture was stirred at -78 °C for 30 min, then at RT overnight. A thick precipitate had formed. The reaction mixture was quenched with saturated aqueous NH_4Cl (14 mL) and poured into EtOAc (50 mL). The phases were separated. The organic layer was washed with saturated aqueous NaHCO_3 (1 x 30 mL), brine (1 x 30 mL), dried (MgSO_4), 20 filtered and concentrated. The residue was purified by flash chromatography using EtOAc as the eluent to afford 801.6 mg (2.4 mmol, 65%) of the desired product. mp 165-167 °C; Anal. Calcd for $\text{C}_{16}\text{H}_{19}\text{FN}_2\text{O}_3\text{S}$: C, 56.79; H, 5.66; N, 8.28; S: 9.48. Found: C, 56.88; H, 5.74; N, 8.21; S: 9.33.

Step 8: (5R)-3-[3-Fluoro-4-(tetrahydro-1*H*-thieno[3,4-c]pyrrol-5(3*H*)-yl)phenyl]-5-[(methylsulfonyl)oxymethyl]-2-oxazolidinone

To a stirred solution of (5*R*)-3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-c]pyrrol-5(3*H*)-yl)phenyl]-5-(hydroxymethyl)-2-oxazolidinone (656.5 mg, 1.9 mmol) in CH_2Cl_2 (20 mL) cooled to 0 °C was added triethylamine (0.41 mL, 2.9 mmol) followed by 30 methanesulfonylchloride (0.18 mL, 2.3 mmol). The reaction mixture was stirred at 0 °C for 15 min, then at RT for 18 h. The reaction mixture was poured into H_2O (20 mL). the phases were separated. The aqueous layer was extracted with CH_2Cl_2 (1 x 50 mL). The combined organic layers were dried (MgSO_4), filtered and concentrated. the residue was triturated with ether/hexane and solid was isolated 35 by filtration and dried to afford 773.9 mg (1.9 mmol, 96%) of the desired mesylate. mp 148-150 °C; Anal. Calcd for $\text{C}_{17}\text{H}_{21}\text{FN}_2\text{O}_5\text{S}_2$: C, 49.03; H, 5.08; N, 6.73; S:

15.40. Found: C, 48.56; H, 5.12; N, 6.48; S: 15.41. Found: C, 48.46; H, 5.25; N, 6.38.

Step 9: (S)-N-[[3-[3-fluoro-4-(tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methylacetamide

5 A stirred suspension of (5*R*)-3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-c]pyrrol-5(3*H*)-yl)phenyl]-5-[(methylsulfonyl)oxy]methyl]-2-oxazolidinone (208.5 mg, 0.5 mmol) in THF (3 mL) and methanolic ammonia (3 mL) was heated in a sealed tube at 100 °C for 48 h. (The reaction mixture became homogenous at about 80 °C.) The cooled 10 reaction mixture was concentrated and the resulting residue was dissolved in CH₂Cl₂ (5 mL) and cooled to 0 °C. To this stirred suspension was added pyridine (0.12 mL, 1.5 mmol) followed by acetic anhydride (60 μL, 0.6 mmol). The homogeneous reaction mixture was stirred at 0 °C for 15 min, then at RT for 1 h then concentrated. The residue was purified by flash chromatography using 7 % 15 methanol in EtOAc as the eluent to afford 148.2 mg (0.4 mmol, 78%) of the desired acetamide. mp 143-144 °C; KF-H₂O: 0.52% Anal. Calcd for C₁₈H₂₂FN₃O₃S plus 0.52% H₂O: C, 56.68; H, 5.87; N, 11.01; S: 8.40. Found: C, 56.31; H, 5.90; N, 10.74; S: 8.30.

20 EXAMPLE 5: (S)-N-[[3-[3-fluoro-4-(tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methylacetamide. S-oxide

To a stirred solution of (S)-N-[[3-[3-fluoro-4-(tetrahydro-1*H*-thieno[3,4-c]pyrrol-5(3*H*)-yl)phenyl]-2-oxo-5-oxazolidinyl]acetamide (216.8 mg, 0.57 mmol) in methanol 25 (4 mL) and H₂O (4 mL) cooled to 0 °C was added sodium metaperiodate (134.4 mg, 0.63 mmol). The reaction mixture was stirred at 0 °C for 1 h, then at RT for 18 h. The solid precipitation was removed by filtration. The solid was washed with CHCl₃ (50 mL). The filtrate was washed with H₂O (1 x 30 mL). The aqueous layer was extracted with CHCl₃ (2 x 25 mL). The combined organic layers were dried 30 (MgSO₄), filtered and concentrated. The residue was purified by flash chromatography using 7% methanol in CH₂Cl₂ as the eluent to afford 195.7 mg (0.5 mmol, 87 %) of the desired sulfoxide. mp 162-164 °C; HRMS (EI) calcd for C₁₈H₂₂FN₃O₄S 395.1315, found 395.1309. KF-H₂O: 2.87 % Anal. Calcd for C₁₈H₂₂FN₃O₄S plus 2.87 % H₂O: C, 53.09; H, 5.76; N, 10.32; S: 7.87. Found: C, 35 53.07; H, 6.01; N, 10.20; S: 7.87.

EXAMPLE 6: (S)-N-[[3-[3-fluoro-4-(tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, S,S-dioxide

To a stirred solution of (S)-N-[[3-[3-fluoro-4-(tetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (213.9 mg, 0.56 mmol) in 25 % acetone/H₂O (8 mL) was added N-methylmorpholine-N-oxide (198.1 mg, 1.7 mmol) followed by osmium tetroxide in *tert*-butanol (2.5 % by wt.) (30 μ L, 0.08 mmol). The reaction mixture was stirred at RT for 18 h. The reaction mixture was quenched by careful addition of saturated sodium bisulfite (8 mL). The mixture was poured into CH₂Cl₂ (50 mL) and the phases were separated. The aqueous phase was extracted with CH₂Cl₂ (2 x 25 mL). The combined organic layers were washed with brine (1 x 30 mL), dried (MgSO₄), filtered and concentrated. The residue was purified by flash chromatography using 7 % methanol in CHCl₃ as the eluent to afford 194.3 mg (0.47 mmol, 84 %) of desired sulfone. mp 135-137 °C; HRMS (EI) calcd for C₁₈H₂₂FN₃O₅S 411.1264, found 411.1263. KF-H₂O: 1.10 %. Anal. Calcd for C₁₈H₂₂FN₃O₅S plus 1.10 % H₂O: C, 51.96; H, 5.45; N, 10.10; S: 7.71. Found: C, 51.73; H, 5.62; N, 9.96; S: 7.75.

EXAMPLE 7: *cis*-(S)-N-[[3-[3-fluoro-4-[3-oxa-7azabicyclo[3.3.0]octane-7-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

Following the general procedure of EXAMPLE 2 and making noncritical variations but substituting hexahydro-1H-furo(3,4-c)pyrrole (Miller, A.D. U.S. Patent 3,975,532 1976). (2.33 g, 20.66 mmol) for (1S, 4S)-2-thia-5-azabicyclo[2.2.1]heptane, the title compound is obtained, mp 124-126°C.

Chart I




Chart II




Chart III






CHART IV

5



10




What is Claimed:

1. A compound of structural Formula I:

5

10



15

Formula I

or a pharmaceutically acceptable salt thereof wherein:

20 X is (a) O,
 (b) S,
 (c) SO,
 (d) SO₂;

R¹ is independently H, F, Cl or OMe;

25 R² is (a) hydrogen,
 (b) C₁-C₈ alkyl optionally substituted with one or more of the following:
 F, Cl, hydroxy, C₁-C₈ alkoxy, C₁-C₈ acyloxy,
 (c) C₃-C₆ cycloalkyl,
 (d) amino,
 30 (e) C₁-C₈ alkylamino,
 (f) C₁-C₈ dialkylamino,
 (g) C₁-C₈ alkoxy;

a is 0 to 3; b is 0 to 2; c is 0 to 2 (provided b and c cannot both be 0); d is 0 to 2;
 and e is 0 to 2 (provided d and e cannot both be 0).

35

2. The compound of Claim 1 wherein X is S.

3. The compound of Claim 1 wherein each R¹ is independently H or F.
4. The compound of Claim 3 wherein each R¹ is F.
5. 5. The compound of Claim 1 wherein R² is hydrogen, a C₁-C₈ alkoxy, or a C₁-C₈ alkyl optionally substituted with one or more Cl or OH.
6. The compound of Claim 1 wherein R² is methyl, dichloromethyl, hydroxymethyl, or methoxy.

10

7. The compound of Claim 1 which is:
 - a) (S)-N-[[3-[3-fluoro-4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - b) (S)-N-[[3-[3-fluoro-4-[(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; or
 - c) (S)-N-[[3-[3-fluoro-4-[(1S,4S)-2-thia-2,2-dioxo-5-azabicyclo[2.2.1]heptan-5-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
8. The compound of Claim 1 which is the S-enantiomer form.

20


9. The compound of Claim 1 wherein c and b are both 1.
10. The compound of Claim 9 wherein d and e are both 1.
- 25 11. The compound of Claim 10 wherein a is 0.
12. The use of a compound of Formula I to prepare a medicament useful in treating microbial infections in a patient in need thereof by administering an effective amount of a compound of Formula I.

30

13. A compound of structural Formula II:

5

10



Formula II

or pharmaceutically acceptable salts thereof wherein:

15 X is (a) O,
 (b) S,
 (c) SO,
 (d) SO₂;

R¹ is independently H, F, Cl or OMe; and

20 R² is (a) hydrogen,
 (b) C₁-C₈ alkyl optionally substituted with one or more of the following:
 F, Cl, hydroxy, C₁-C₈ alkoxy, C₁-C₈ acyloxy,
 (c) C₃-C₆ cycloalkyl,
 (d) amino,
 25 (e) C₁-C₈ alkylamino,
 (f) C₁-C₈ dialkylamino,
 (g) C₁-C₈ alkoxy.

14. The compound of Claim 13 which is the S-enantiomer form.

30

15. The use of a compound of Formula II to prepare a medicament useful in treating microbial infections in warm-blooded animals by administering to a patient in need thereof an effective amount of a compound of Formula II.

35

INTERNATIONAL SEARCH REPORT

Intern. Appl. No
PCT/US 95/12751

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D491/048 C07D491/08 C07D495/04 C07D495/08 A61K31/42
 // (C07D491/048, 307:00, 209:00), (C07D491/08, 307:00, 209:00),
 (C07D495/04, 333:00, 209:00), (C07D495/08, 333:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 23384 (UPJOHN) 25 November 1993 see claims 1,11 ---	1, 12, 13, 15
A	JOURNAL OF MEDICINAL CHEMISTRY., vol.33, no.9, 1990, WASHINGTON US pages 2569 - 2578 W. A. GREGORY ET AL 'Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group' cited in the application see table VI ---	1, 12, 13, 15
P, X	WO,A,95 07271 (UPJOHN) 16 March 1995 cited in the application see claims 1,15 ---	1, 12 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

2

Date of the actual completion of the international search

Date of mailing of the international search report

6 February 1996

14.02.1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Voyiazoglou, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/12751

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,95 14684 (UPJOHN) 1 June 1995 see claims 1,9 -----	1,12,13, 15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/12751

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9323384	25-11-93	AU-B-	4287793	13-12-93
		CN-A-	1079964	29-12-93
		CZ-A-	9402505	16-08-95
		EP-A-	0640077	01-03-95
		FI-A-	945246	08-11-94
		JP-T-	7506829	27-07-95
		NO-A-	944237	04-01-95
		SK-A-	133794	07-06-95
WO-A-9507271	16-03-95	AU-B-	7557094	27-03-95
WO-A-9514684	01-06-95	AU-B-	8010394	13-06-95